[{"data":1,"prerenderedAt":30},["ShallowReactive",2],{"fbq-id":3,"news-en-olpha-strengthens-its-position-in-europe-with-a-new-generic-cardiology-medication":4},"229099849130020",{"data":5,"error":23,"breadcrumbs":24},{"detailImage":6,"detailImageAlt":10,"title":11,"url":12,"seoTitle":11,"seoDescription":10,"seoKeywords":10,"seoRobots":13,"date":14,"body":15,"i18n":20},{"url":7,"width":8,"height":9},"/uploads/large_Olpha_jaunais_medikamentus_full_2312991a2f.jpg",900,601,"","“Olpha” strengthens its position in Europe with a new generic cardiology medication","olpha-strengthens-its-position-in-europe-with-a-new-generic-cardiology-medication","index, follow","10.04.2026.",[16],{"__component":17,"id":18,"text":19},"article-body.text",745,"**Latvian pharmaceutical manufacturer AS “Olpha” has launched its fourth generic cardiology product within two years. Currently, these medicines produced by AS “Olpha” have entered the pharmaceutical markets of seven European Union (EU) countries, including Latvia, Lithuania, and Estonia.**\n\nCardiovascular diseases are the leading cause of death and disability in the EU. Approximately 1.8 million people die from them each year. The new generic prescription medicine by “Olpha” reduces the formation of blood clots, which can lead to life-threatening heart attacks or strokes.\n\n> “The development of generic medicines, which is our current focus, is essential both in the interests of patients and for strengthening the resilience of the entire healthcare system. The entry of new products into the market and increasing competition bring clear benefits—they improve access to medicines, provide doctors and pharmacists with broader choices in patient care, and, in Latvia’s case, also reduce the high dependence on imported medicines. At the same time, every medicine offered by Latvian manufacturers makes a significant economic contribution by strengthening the local pharmaceutical industry and increasing the resilience of the national healthcare system,” **emphasizes AS “Olpha” Chairman of the Board, Dr. chem. Juris Hmeļņickis.**\n\nWith its new generic medicine, “Olpha” has won a public procurement tender in Italy’s Marche region for supplying medicines to its hospitals over the next three years.",{"en":21,"lv":22},"/en/news/olpha-strengthens-its-position-in-europe-with-a-new-generic-cardiology-medication","/jaunumi/olpha-stiprina-pozicijas-eiropa-ar-jaunu-patentbrivo-kardiologijas-medikamentu",[],{"title":11,"list":25},[26,29],{"text":27,"url":28},"News","news",{"text":11},1777197334587]